摘要
目的探讨高同型半胱氨酸血症(HHcy)与急性脑梗死患者尿激酶静脉溶栓治疗效果的关系。方法选取2012年4月~2015年5月云浮市人民医院收治的急性脑梗死患者91例,测定患者空腹时血浆同型半胱氨酸(Hcy)浓度,将其分为HHcy组(48例)和非HHcy组(43例)。所有患者均给予尿激酶静脉溶栓治疗,治疗时间均为2周,观察两组神经功能缺损程度、临床治疗效果、日常生活能力、血管再通情况、不良反应发生情况。结果治疗前两组NIHSS评分比较差异无统计学意义(P>0.05);治疗12 h、48 h、7 d两组NIHSS评分均显著低于治疗前(P<0.05),且同期组间比较非HHcy组显著低于HHcy组(P<0.05),两组治疗48 h均较治疗12 h显著降低(P<0.05),两组治疗7 d均较治疗48 h显著降低(P<0.05);非HHcy组总有效率显著高于HHcy组(P<0.05);非HHcy组生活自理率显著高于HHcy组(P<0.05);非HHcy组再通率显著高于HHcy组(P<0.05);HHcy组不良反应发生率显著高于非HHcy组(P<0.05)。结论采用尿激酶静脉溶栓治疗急性脑梗死,非HHcy患者可显著改善神经功能缺损,提高日常生活能力和临床治疗效果。
Objective To investigate the relationship between hyperhomocysteinemia （HHcy） and intravenous thrombolytie therapy of urokinase in patients with acute cerebral infarction. Methods From Apirl 2012 to May 2015, in Yunfu City People＇s Hospital, 91 patients with acute cerebral infarction were selected, the plasma homocysteine （Hey） concentration was measured and they were divided into HHey group （48 cases） and non-HHcy group （43 cases）. All patients were treated with intravenous thrombolytie therapy of urokinase, the treatment time was 2 weeks, the neurological deficits, clinical treatment effect, daily living ability, vascular reeanalization and incidence of adverse reactions were observed. Results The NIHSS scores of the two groups before treatment were not statistically significant （P 〉 0.05）. The NIHSS scores of the two groups at 12 h, 48 h and 7 d were significantly lower than those before treatment （P 〈 0.05）, these of non-HHcy group were lower than those of HHey group at the same time （P 〈 0.05）,these of the two groups at 48 hwerelower than those at 12 h （P〈 0.05）,these of the two groups at 7 d were lower than those at 48 h （P〈 0.05）. The effective rate of non-HHey group was significantly lower than that of HHcy group （P 〈 0.05）, and the total effective rate of non-HHey group was significantly lower than that of HHey group （P 〈 0.05）. The life self-care rate of non-HHcy group was significantly higher than that of HHcy group （P 〈 0.05）. The recanalization rate of non-HHey group was significantly higher than that of HHey group （P 〈 0.05）. The incidence of adverse reactions in HHcy group was significantly higher than that in non-HHey group （P 〈 0.05）. Conclusion The using of urokinase intravenous thrombolysis in the treatment of acute cerebral infarction, non-HHcy patients can significantly improve neurological deficits, improve daily living ability and clinical treatment.
出处
《中国医药导报》
CAS
2017年第25期54-57,共4页
China Medical Herald
关键词
同型半胱氨酸血症
急性脑梗死
尿激酶
静脉溶栓
Homocysteineemia
Acute cerebral infarction
Urokinase
Intravenous thrombolysis
